Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02285673|
Recruitment Status : Unknown
Verified November 2014 by Ercument Ovali, Acibadem University.
Recruitment status was: Recruiting
First Posted : November 7, 2014
Last Update Posted : November 7, 2014
Duchenne muscular dystrophy (DMD) is a genetic disorder caused by an absence of dystrophin and characterized by progressive muscle degeneration. There is no cure for DMD at present but, there are several strategies under-researched for treatment of DMD such as steroid treatment, gene theraphy, exon skipping, stop codon read through and gene repair, cell theraphy and theraphy with drug that help to produce utrophin protein.
The aim of this study is investigate the eficacy of human umblical cord mesenchymal stem cells on DMD and understanding if wild type gene can be transfered to the patient.
|Condition or disease||Intervention/treatment||Phase|
|Duchenne Muscular Dystrophy||Biological: Umbilical Cord Mesenchymal Stem Cell||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy: Phase 1/2 Study|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||February 2015|
|Estimated Study Completion Date :||November 2015|
|Experimental: Umbilical Cord Mesenchymal Stem Cell||
Biological: Umbilical Cord Mesenchymal Stem Cell
Other Name: umbilical cord mesenchymal stem cells
- Duchenne muscular dystrophy gene expression [ Time Frame: up to 9 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02285673
|Contact: Ercument Ovali, Prof.Dr.||+firstname.lastname@example.org|
|Contact: Cengiz Yakicier, Prof.Dr.||email@example.com|
|Istanbul, Uskudar, Turkey, 34662|
|Contact: Ercument Ovali, Prof. Dr. +905325729174 firstname.lastname@example.org|